Cancer Immunology, Immunotherapy

Show Articles
Journal Properties
  • Country
    Germany
  • Language
    English
  • Number of Articles
    25
  • Abbreviation
    Cancer Immunol, Immunother
  • ISSN
    0340-7004
  • Main Publisher
    Springer Nature
  • Publisher
    Springer Science and Business Media LLC
  • Indian UGC
  • Indian UGC Name
  • DOAJ (latest)
Journal Properties
  • Final Decision (day)
    98
  • Medicine
    Internal medicine
    Neoplasms
    Tumors
    Oncology
    Including cancer and carcinogens
    Medicine
    Internal medicine
    Specialties of internal medicine
    Immunologic diseases
    Allergy
  • website
Description
Cancer Immunology, Immunotherapy (CII) is a leading journal focused on translational and clinical studies in cancer immunology and immunotherapy. It provides a platform for groundbreaking research exploring immune mechanisms in cancer development and novel immunotherapeutic strategies. CII covers a broad spectrum of topics, from basic research on tumor-immune interactions to clinical trials of immunotherapeutic interventions. Key areas include immune checkpoint inhibitors, adoptive cell therapy, cancer vaccines, and oncolytic viruses. Indexed in major databases such as CAS, Scopus, and Web of Science, CII is a valuable resource for cancer researchers, immunologists, and clinicians. The journal promotes the rapid dissemination of impactful findings in cancer immunology and immunotherapy. Contribute your research to advance the fight against cancer through innovative immune-based approaches.
Directory of Open Access Journals (DOAJ)
There is further information about this journal. Please follow links.